ShangHai Stock Connect
- 1166.517
- -20.345-1.71%
Suspected of major financial fraud! Orient Group Incorporation is currently at risk of being (Delisted). How can the rights of 0.129 million Shareholders be protected?
① The China Securities Regulatory Commission reported that it has preliminarily determined that the financial information disclosed by Orient Group Incorporation from 2020 to 2023 is severely inaccurate, suspected of significant financial fraud, which may involve serious violations that lead to (Delisted); ② As of the end of the third quarter of 2024, Orient Group Incorporation still has 0.129 million Shareholders, raising concerns about how investors can protect their legal rights.
The amount involved exceeds 0.5 billion yuan and the equity transfer dispute of China Meheco Group is still ongoing | Quick read of the announcement.
① China Meheco Group has appealed to the court regarding the acquisition of the remaining 30% equity in Jinlun Pharmaceutical (now named Hebei Tongyong) held by Wang Yibing; ② The amount involved in this lawsuit reaches 0.51 billion yuan.
Wang Xingxing stated that "this year humanoid robots will reach a new level," Zhejiang XCC Group plans to invest 1.5 billion in the screw project | Brief announcement.
① After expanding the screw rod production capacity by changing part of the fundraising projects in September last year, Zhejiang XCC Group plans to invest 1.5 billion yuan to construct projects such as planetary roller screws; ② Zhejiang XCC Group stated that the past two years have been an important stage for the company's business transformation and upgrading, focusing on the new screw rod business; ③ Recently, Wang Xingxing, the founder of Yushu Technology, mentioned that the entire AI humanoid robot is expected to reach a new level by the end of this year.
The first annual report on computing power chips of the year has been released! Haiguang Information's 2024 revenue is expected to increase by over 50%, significantly increasing inventory four times to ensure supply.
① Haiguang Information released its 2024 financial report, with revenue of 9.152 billion yuan, a 52.40% increase compared to the same period last year, and a year-on-year increase of 52.87% in Net income attributable to the parent company; ② Haiguang Information stated that the industrial ecosystem of its high-end processor products is continually expanding, with increased applications in various Industries and the emerging AI large model industry, leading to a 405.09% year-on-year increase in inventory value by the end of 2024.
Star Evening Report | Haiguang Information's net profit in 2024 increased by over 52% year-on-year, and the Fund has reduced its Shareholding in Tailin Micro by 1%.
Today's Star evening news mainly includes: Peking releases an action plan to promote the landing of 10,000 units of embodiment Siasun Robot&Automation; National Silicon Industry Group: plans to purchase minority equity and other Assets, Stocks continue to be suspended for no more than 5 Trading days; Saifang Semiconductors secures Pre-B round financing.
Investing in industry funds + establishing a joint venture, Cathay Biotech Inc. "leverages" Contemporary Amperex Technology and Hefei State Assets.
① Behind Cathay Technology are two major giants, Cathay Biotech Inc. and Contemporary Amperex Technology. ② Cathay Technology mainly engages in the research, production, and sales of products applying Cathay Biotech Inc.'s polyamide composite materials in the fields of power batteries, energy storage, and other New energy areas. ③ The招商凯赛新材料基金 (Zhaoshang Cathay New Materials Fund), co-founded by Cathay Biotech Inc., Hefei State-owned Assets, and China Merchants Shekou Industrial Zone Holdings, was established with a registered capital of 0.65 billion yuan.
The American "god car" has unleashed its ultimate weapon.
Jump squat.
In some Industries, investment has slowed down alongside changes in demand structure, resulting in a decline in both revenue and net profit for Lingyun in 2024.
① Recently, the humanoid robots of Yushu Technology have attracted the attention of investors in the Capital Markets, and the stock price of Lingyun Guang, as a "Robot Concept stock," has shown significant fluctuations; ② The company stated that as of now, the total service revenue provided to Yushu Technology is only 0.01 million yuan, and there are no outstanding Orders from Yushu Technology.
CanSino Biologics Inc.'s losses narrowed by more than 70% in 2024, driven by the launch of the innovative four-component vaccine, boosting revenue.
① Revenue has significantly increased compared to the same period last year, mainly because its vaccine product, Manhai Xin, is the only quadrivalent meningococcal conjugate vaccine in the China market, which has continuously improved its product penetration over the past year, achieving rapid sales growth. ② CANSINOBIO's Chief Commercial Officer Wang Jing has stated that based on the current vaccine pipeline under development, CANSINOBIO has successfully built a comprehensive commercialization operation system.
AI helps reduce costs and improve efficiency in drug development. The "AI+Medical" Industry has explosive growth opportunities.
China Post Securities pointed out that the Global market size for AI+Medical industry AI solutions is expected to increase from 13.7 billion dollars in 2022 to 155.3 billion dollars in 2030, with a CAGR of 35.5%, indicating explosive growth opportunities in the industry.
BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript Summary
Longxun Co., Ltd. expects revenue and net profit to increase by more than 40% in 2024, with Q4 performance reaching a new high. However, pressure from technological iterations has caused delays in the construction of fundraising projects.
① The Earnings Reports released by Longxun Co., Ltd. for the fiscal year 2024 show that revenue reached 0.466 billion yuan, an increase of 44.21% year-on-year, and the Net income attributable to the parent company grew by 40.62% year-on-year, with Q4 revenue and Net income both hitting record highs; ② Due to the rapid iteration of technology in the industry, customer demand and market competition are also constantly evolving, Longxun Co., Ltd. announced on the same day as the annual report disclosure that the construction of some of its initial public offering fundraising projects will be delayed.
Increased revenue but no profit! Jiangsu Cnano Technology Co., Ltd.'s net profit in 2024 decreased by more than 10% year-on-year.
① Jiangsu Cnano Technology Co.,Ltd. stated that as the company vigorously expands its overseas customer base, it is expected that product demand will continue to grow with market demand by 2025; ② Looking ahead to future market expectations, Jiangsu Cnano Technology Co.,Ltd. expects that product demand will continue to grow with market demand by 2025.
40 billion! BBMG Corporation breaks through financing, still spending billions in Beijing during the period of losses.
① The longstanding state-owned enterprise BBMG Corporation has received approval for financing of up to 40 billion, sparking heated discussions in the market; ② BBMG Corporation has performed poorly in recent years, and for 2024, it is expected that the adjusted Net income loss will be between 2.8 billion and -3.1 billion yuan, yet it continues to spend hundreds of millions to acquire land in Beijing during this loss period.
Star Evening Report | BEIGENE expects revenue of 35.2-38.1 billion yuan in 2025. Huazhu High-Tech Shareholders intend to reduce their Shareholding by no more than 2%.
① Two departments: Increase financial support for charging infrastructure. ② Zhejiang is piloting the use of quadrupedal robots in the civil aviation sector for the first time. ③ Lei Jun: R&D investment is expected to reach 30 billion yuan by 2025.
The downstream market demand is expanding, and Novoray Corporation plans to invest 0.3 billion yuan to establish a project for ultra-pure spherical powder materials.
① A representative from the company's secretariat stated that they have relatively mature products and have gone through many rounds of process scaling; ② Novoray Corporation indicated that the products from the aforementioned project currently account for a small proportion of the company's revenue, and after the project is completed, it will further expand the production scale of the company's high-end spherical powder materials.
The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus
① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.
The main line of Technology continues to evolve, and the AI computing power sector is expected to gain strength.
Track the entire lifecycle of the main Sector.
Why did Zhongjin and Silver once again become the "main characters of rumors" after the overnight announcement denying the merger?
"The truth and falsehood of 'stock swap mergers.'"
Will pay over 30 million equity dispute amounts. Getein Biotech, Inc has issued multiple lawsuit announcements in the past four months | Brief announcement.
① Getein Biotech, Inc and nine minority shareholders of Jingchuan Diagnostics, including Wuhan Boruihong, have received a final judgment in their equity acquisition dispute. ② According to the judgment, Getein Biotech, Inc will pay over 30 million yuan for the acquisition.